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OBJECTIVE — The purpose of this study was to determine how patients’ beliefs about anti-
hyperglycemic and antihypertensive medications relate to medication underuse and health
status.
RESEARCH DESIGN AND METHODS — In diabetic patients from an economically
distressed region, we assessed perceived necessity and harmfulness for antihyperglycemic (n 
803) and antihypertensive (n  573) medications, past year’s medication underuse, A1C,
systolic blood pressure (SBP), and diastolic blood pressure (DBP).
RESULTS — After correction for multiple analyses, multivariate models indicated that per-
ceived need for antihyperglycemic medication was associated with being younger, being pre-
scribed insulin, and being prescribed multiple medications. Concern about antihyperglycemic
medicationswasassociatedwithbeingyounger,AfricanAmerican,dissatisﬁedwithinformation
receivedaboutmedication,andoflowhealthliteracy.Forantihypertensives,perceivednecessity
was associated with having numerous medical comorbidities and being dissatisﬁed with medi-
cation information; concern was associated with being younger, dissatisﬁed with information
received about medication, and of low health literacy. Up to one-half of patients underused at
least one of the types of medication; many of these patients attributed this underuse to cost. For
both types of medications, concern was signiﬁcantly associated with both cost-related and
non–cost-related underuse, and antihypertensive concern was associated with higher SBP
and DBP.
CONCLUSIONS — Even after adjustment for economic factors, patients who are younger,
African American, or of low health literacy are especially concerned about medication harmful-
ness, which is in turn associated with medication underuse and higher blood pressure. To
enhance adherence and outcomes, interventions should address patients’ underlying concerns
about potential adverse treatment effects and focus on both cultural factors and health literacy.
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D
espite advances in pharmacother-
apy and decades of intervention tri-
als to improve diabetes self-
management support, adherence to
diabetes medication regimens remains
suboptimal(1).However,adherenceisan
“overdetermined” behavior insofar as it is
inﬂuenced by a diverse variety of demo-
graphic, psychosocial, and economic fac-
tors. In this study, we focus on one of the
least studied of these factors, patients’
personalbeliefsabouttheirtreatment,be-
causethisconstructseemstobeanadher-
ence determinant in other illnesses and is
potentially modiﬁable through educa-
tional and psychosocial interventions.
On both conceptual and empirical
bases,treatmentbeliefscanbesubdivided
into adherence-increasing beliefs about
treatment necessity and advantages and
adherence-reducing beliefs about treat-
ment harmfulness, risks, and barriers.
Various forms of these constructs seem to
explainadherencevariationacrossseveral
prevalent chronic illnesses, including
HIVinfection(2),depressivedisorder(3–
5), and cardiovascular disease (6). Al-
thoughbeliefsalsoappeartoplayarolein
diabetes adherence, this conclusion is
based mainly on single items from scales
designedtomeasureotherconstructsand
other nonstandardized measures (7,8).
The nature, intensity, and impact of
medication beliefs may vary across socio-
demographic subgroups. For example,
lower-income patients may be more fatal-
istic about their likelihood of negative ill-
ness outcomes and, as a consequence, be
less motivated to pursue aggressive man-
agement or “tight control” regimens (9–
12). Researchers and clinicians are also
increasingly concerned about variation in
health care trust, perceived discrimina-
tion, and outcomes between African
American and Caucasian patients (7). Po-
tential variations in diabetes treatment
perceptions may provide an important
window into these disparities.
In this current study, we examined
diabetic patients’ beliefs about their med-
ication necessity and potential harmful-
ness in an economically distressed
community. Given the importance of hy-
pertensionmanagementfordiabetescare,
we also studied diabetic patients’ beliefs
about their antihypertensive medications
if applicable. After analyzing covariation
in beliefs and sociodemographic charac-
teristics, we modeled multivariate associ-
ations among beliefs, nonadherence (due
to either cost or other reasons), and key
medical outcomes.
RESEARCH DESIGN AND
METHODS— This study was con-
ducted in Flint, Michigan, an economi-
cally distressed, midsized city. Patients
were identiﬁed from general medicine
clinics of a large safety-net health system
(17% of participants), its afﬁliated diabe-
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networkoffederallyqualiﬁedcommunity
health centers (25%). Most (92%) were
identiﬁed from electronic and paper
records using diagnostic codes and re-
cruited via telephone. Additional partici-
pants were recruited during outpatient
visits. Patients were eligible for the study
if they had type 2 diabetes, used antihy-
perglycemic medication, had not been
hospitalized in the prior 3 years for seri-
ous psychiatric illness, and received most
of their diabetes care in a participating
site. Between July 2005 and December
2007,3,800patientswereidentiﬁedfrom
medical records and screened by phone,
and322wereidentiﬁedasoutpatients.Of
this pool of 4,122 patients contacted for
screening and recruitment, 2,516 could
not be reached, 450 refused, and 1,116
were screened. Of those contacted, 841
were determined to be eligible and 806
(96%) participated. The study was ap-
proved by ethics committees at the Uni-
versity of Michigan and participating
health systems.
Data collection and variable creation
Date were collected by face-to-face re-
search interviews conducted by research
staff from various racial backgrounds.
Surveyitemsassessedmedicationuseand
beliefs, communication with clinicians,
healthstatus,andsociodemographicvari-
ables. A Bayer 2000 analyzer was used to
determine A1C. Blood pressure was mea-
sured from each arm with an Omron au-
tomatic blood pressure monitor and an
appropriately sized cuff and averaged to-
gether with a third measure taken 2 min
later from the arm with the higher reading.
Medication beliefs
Patients’ treatment beliefs were measured
using a well-validated scale, the Beliefs
about Medications Questionnaire (BMQ)
(13), with versions for antihyperglycemic
and antihypertensive medications. The
BMQ consists of 11 items tapping either
perceived medication necessity (5 items,
e.g., “My health, at present, depends on
my [diabetes/high blood pressure] medi-
cation.”) or concern (6 items, e.g., “I
sometimes worry about the long-term ef-
fectsofmy[diabetes/highbloodpressure]
medicine.”) paired with 5-point Likert
scales ranging from “strongly agree” to
“strongly disagree.” Item means are com-
puted for the Necessity and Concerns
subscales. Internal consistency for our
medication-speciﬁc adaptations was sug-
gested by respective Cronbach s of 0.78
and 0.68 for the antihyperglycemic ver-
sion and 0.81 and 0.73 for the antihyper-
tensive version.
Satisfaction with medication
information
Patients’perceptionoftheadequacyofin-
formation about their prescription medi-
cation was measured using a modiﬁed
version of the Satisfaction with Informa-
tion about Medications Scale (14). This
16-item scale covers satisfaction with in-
formation received “from doctors and
otherpeopleworkingintheplacewhere
I get medical care” on topics such as
medication effectiveness. Based on pre-
testing, the 5-point Likert scale used
was replaced with simpliﬁed choices
(“enough”versus“notenough”).There-
vised measure had  of 0.89 in this
dataset. Higher scores indicate greater
satisfaction, and a median split was per-
formed to facilitate interpretation.
Medication underuse
Cost-related underuse was measured us-
ing an item that has been used in several
prior studies, “In the past 12 months,
haveyouevertakenlessofyour[diabetes/
hypertension] medication than pre-
scribed by your doctor because of the
cost?” Non–cost-related underuse was
measuredusingtheitem“Manypeopledo
nottaketheirprescriptionmedicationex-
actly as prescribed by their doctor. In the
pastyear,haveyouevertakenlessofyour
[diabetes/hypertension] medication pre-
scribed for any reason other than the
cost?”
Other variables
Race/ethnicity was self-reported. Func-
tionalhealthliteracy(FHL)wasmeasured
using three previously validated items
(15). As previously validated against a
widely accepted standard (16,17), an
FHL deﬁcit was indicated by difﬁculty
reading forms or learning about medical
conditions. Other self-reported variables
were educational attainment, income, in-
sulin prescription, and monthly out-of-
pocket medication costs categorized
reduced by median split ($49 vs.
$50).
Statistical analysis
We initially considered bivariate associa-
tions between selected patient character-
istics(e.g.,sociodemographicvariablesor
satisfaction)andmedicationbeliefs,using
Spearman’s  correlation and matched-
samples t tests. We then developed four
multivariate ordinary least-squares re-
gression models to evaluate the indepen-
dent effect of patient characteristics on
medication beliefs. Next, multinomial lo-
gistic models were ﬁtted to examine the
impact of perceived necessity and con-
cerns (evaluated simultaneously, i.e., in
thesamemodel)oncost-relatedandnon–
cost-related medication underuse. Fi-
nally, ordinary least-squares regression
models were ﬁtted to examine the inﬂu-
ence of perceived necessity and concerns
(also evaluated simultaneously) on A1C,
systolic blood pressure (SBP), and dia-
stolicbloodpressure(DBP).Becausemul-
tivariate analyses involved ﬁve outcomes,
we applied a Bonferroni correction by
interpreting only effects that reached
the P  0.01 (Pcrit  0.05/5) level of
signiﬁcance.
RESULTS
Descriptive statistics
Sample characteristics are summarized in
Table 1. Slightly more than half of the
samplewasAfricanAmericanandslightly
more than half was female. More than
one-third had low FHL. Participants
showedreasonablygoodglycemiccontrol
(mean  7.8%) and blood pressure con-
trol (mean SBP/DBP  139/83 mmHg).
The majority (71%) were prescribed an
antihypertensive medication. The only
detected difference between participants
who were prescribed antihypertensive
medication and those who were not was
that the former had higher SBP and DBP
than the latter (both P  0.01). Beliefs
aboutbothmedications(summarizedin
Table 1) varied across their entire pos-
siblerangesandapproximatedanormal
distribution.
Univariate associations with
medication beliefs
Matched-samplest tests indicated that for
both types of medication, perceived neces-
sity was stronger than concern (respective
mean differences were 1.0 and 1.1 units on
the 5-point BMQ scale [or 1.7 and 1.8 SD
units], both P  0.0001). Participants pre-
scribed both types of medication rated an-
tihyperglycemic medication as more
necessary (P  0.001) and more concern-
ing (P  0.0001) than antihypertensive
medication,althoughtheseeffectsizeswere
relativelysmall(meandifferenceswereboth
0.1 BMQ unit or 0.17 SD units).
Bivariateassociationsbetweenpatient
characteristics and medication beliefs are
listed in Table 2. These were fairly consis-
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Perceived medication necessity tended to
be stronger among participants who were
younger, female (antihypertensive beliefs
only), affected by more comorbid condi-
tions, prescribed a higher number of
medications, or prescribed insulin (anti-
hyperglycemic beliefs only). Perceived
harmfulnesstendedtobestrongeramong
participants who were younger, African
American, of low income, affected by a
greater number of comorbid conditions
(antihyperglycemic beliefs only), dissatis-
ﬁed with medication information, or of
low FHL.
Multivariate models of medication
beliefs
Antihyperglycemic medication beliefs.
After adjustment for sociodemographic
covariates (age, sex, ethnicity, and in-
come), perceived need for antihypergly-
cemic medications was independently
associated with having a greater number
of prescriptions and being prescribed in-
sulin(Table3).Incontrast,concernabout
antihyperglycemic medications was asso-
ciated with dissatisfaction with medica-
tion information, low FHL, and high out-
of-pocket prescription costs.
Antihypertensive medication beliefs.
After covariate adjustments, perceived
need for antihypertensive medications
wasassociatedwithhavingagreaternum-
berofcomorbidconditionsandbeingsat-
isﬁed with medication information.
Concern about antihypertensive medica-
tions was associated with being dissatis-
ﬁed with medication information and
having a low FHL.
Multivariate models of adherence
and health status
Antihyperglycemic medication under-
use. Almost half (46.6%) of participants
reported antihyperglycemic underuse,
about one-third of whom (16.5% of all
participants) reported cost-related unde-
ruse. Adjusted logistic regression models
indicated that greater concern was associ-
ated with antihyperglycemic medication
underuse (Table 3). Speciﬁcally, each
Table 1—Sample characteristics
Medication prescribed
Antihyperglycemic
Antihyperglycemic plus
antihypertensive
n 803 573
Age (years) 55.3  11.8 57.2  10.7
Sex (% male) 38.4 31.7
African American 58.3 61.9
Level of education (%)
12 years 21.6 22.8
12 years (high school degree) 35.7 36.6
12 years 42.7 40.6
Household income bracket (%)
$0–$10,000 30.2 32.5
$11,000–$20,000 23.7 24.4
$21,000–$30,000 7.4 6.9
$31,000–$60,000 20.2 19.6
$60,000 18.5 17.0
No. of medical conditions 2.7  1.9 3.0  1.9
No. of prescription medications 4.3  1.2 4.6  1.0
Prescribed insulin (%) 39.9 41.8
A1C 7.8  2.0 7.7  2.0
SBP (mmHg) 139.2  21.2 142.0  22.5
DBP (mmHg) 83.1  12.0 83.7  12.8
Low health literacy (%) 37.2 39.5
Has a primary care provider (%) 75.1 73.0
Prior diabetes education (%) 60.2 59.8
Medication beliefs
Necessity 3.8  0.6 3.7  0.6
Concerns 2.8  0.7 2.7  0.6
Data are mean  SD or %.
Table 2—Bivariate associations between patient characteristics and medication beliefs
Medication beliefs
Antihyperglycemic Antihyperglycemic
Necessity Concerns Necessity Concerns
n 803 573
Age (years) 0.11*** 0.18*** 0.09* 0.16***
Sex (male) 0.03 0.07* 0.11** 0.02
Ethnic minority 0.04 0.11*** 0.00 0.09*
Level of education 0.02 0.01 0.07 0.02
Household income bracket 0.08* 0.09* 0.05 0.14***
Number of prescription medications 0.22*** 0.05 0.18*** 0.004
Prescribed insulin 0.28*** 0.06 0.05 0.03
Number of medical conditions 0.21*** 0.12*** 0.18*** 0.07
Satisfaction with medication information 0.03 0.16*** 0.10* 0.17***
Low functional health literacy 0.01 0.14*** 0.03 0.23***
Out-of-pocket prescription costs $50/month 0.08* 0.05 0.08 0.03
Cell entries represent Spearman’s  values.*P  0.05;**P  0.01;***P  0.005.
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scale was associated with a 2.8 times in-
crease in the risk of cost-related antihy-
perglycemic medication underuse and
alsowitha1.7timesincreaseintheriskof
antihyperglycemic medication underuse
for other reasons (each compared with no
underuse). Antihyperglycemic medica-
tion concern was furthermore associated
with whether a patient reported reduced
adherence because of cost problems or
other reasons. Speciﬁcally, each 1-point
Concerns scale increase was associated
with a 1.7 times increase in the risk of
underusebecauseofcostversusotherrea-
sons. Figure 1 (left panel) depicts this set
of differences.
Diabetes outcomes. Neither antihyper-
glycemic medication necessity nor con-
cern was signiﬁcantly associated with
A1C. However, the regression coefﬁcient
for antihyperglycemic medication con-
cern nearly reached the Bonferroni-
adjustedsigniﬁcancelevel(	0.08,P
0.034) (Table 3).
Antihypertensive medication under-
use. Of participants prescribed anti-
hypertensive medications, 31.1% reported
underuse, with cost being a reason for
underuse for about half (i.e., 15.3% of
those prescribed antihypertensive medi-
cations). As found for antihyperglycemic
medications, concern was signiﬁcantly
associated with each type of underuse
(versus no underuse), but perceived ne-
cessity was not (Table 3). Speciﬁcally,
each1-pointincreaseinConcernswasas-
sociated with a 2.6 times increase in risk
of cost-related antihypertensive medica-
tionunderuseandwitha1.9timesincrease
in risk of antihypertensive medication
underuse for other reasons, each versus
no underuse (Fig. 1, right panel). How-
ever, among those with one or the other
form of antihypertensive medication un-
deruse, concern was not associated with
type of underuse.
Hypertension outcomes. Perceived an-
tihypertensivemedicationnecessitywas
not signiﬁcantly associated with either
SBP or DBP. However, concern was sig-
niﬁcantly associated with both SBP and
DBP(Table3).Extrapolatingfrom	 co-
efﬁcients and SDs obtained, each
1-point increase in the Concerns score
was associated with a 5.7-mmHg in-
crease in SBP and with a 2.5-mmHg in-
crease in DBP. To examine whether this
effect of concern was mediated by
underuse,weaddedtothemodelavari-
able reﬂecting the presence of any
underuse. Although underuse was signiﬁ-
cantlyassociatedwithSBP(	0.14,P
0.002), 	 (concerns) did not decrease ap-
preciably reduce (Preduction in 	  0.21).
The same pattern was found when DBP
was analyzed as the dependent variable
andalsowhenadjustmentforeachtypeof
underuse was coded individually.
CONCLUSIONS — In this study
conducted in an economically vulnerable
community, diabetic patients reported
signiﬁcant concerns about the necessity
and safety of their antihyperglycemic and
Table 3—Multivariate associations between beliefs, adherence, and health status
Independent variables predicting
medication beliefs
Medication beliefs (as dependent variables)†
Antihyperglycemic Antihypertensive
Necessity Concerns Necessity Concerns
n 803 573
Age (years) 0.12*** 0.17*** 0.08 0.17***
Sex (male) 0.02 0.05 0.10* 0.05
Ethnic minority 0.03 0.12*** 0.03 0.09*
Household income bracket 0.08* 0.05 0.04 0.07
Number of prescription medications 0.12** 0.02 0.07 0.06
Whether prescribed insulin 0.23*** 0.03 0.06 0.04
No. of medical conditions 0.09 0.11* 0.14** 0.08
Satisfaction with medication information 0.05 0.15*** 0.11*** 0.14***
Low functional health literacy 0.02 0.12*** 0.01 0.22***
Out-of-pocket prescription costs $50/month 0.05 0.09* 0.07 0.04
Binary dependent variables (medication underuse)‡
Medication beliefs (as independent variables)§
Antihyperglycemic Antihypertensive
Necessity Concerns Necessity Concerns
Cost-related underuse vs. no underuse 1.4 2.8*** 1.2 2.6***
Noncost-related underuse vs. no underuse 1.0 1.7*** 1.2 1.9***
Cost-related underuse vs. non-cost-related underuse 1.4 1.7*** 1.0 1.3
Continuous dependent variables (health status)
A1C (%) 0.03 0.08* — —
SBP (mmHg) — — 0.09* 0.16***
DBP (mmHg) — — 0.07 0.12**
*P0.05(NSwithBonferronicorrection).**P0.01.***P0.005.†Eachcolumnrepresentsaseparateordinaryleast-squaresregressionmodel,withdependent
variables listed as column headers and independent variables listed in rows. Cell entries represent standardized regression coefﬁcients. ‡Cell entries are odds ratios
(Pvalue)ofadjustedassociationbetweenmedicationbeliefs(independentvariable,incolumns)andunderuseofthecorrespondingmedication(dependentvariable,
in rows), with the second type of underuse as the reference group. §All models adjusted for age, sex, ethnic minority status, household income, number of
prescription medications, insulin use, number of comorbid conditions, out-of-pocket prescription costs, and FHL. Cell entries are standardized 	 coefﬁcients (P
value) of adjusted association between medication beliefs and the medical outcome variable.
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the strongest concerns about medication
harmfulness tended to underuse both
types of medication because of both cost
and other reasons. Concern was further-
more associated with blood pressure con-
trol among patients prescribed
antihypertensive medications. These as-
sociationspersistedafterstatisticaladjust-
ment for multiple sociodemographic
factors, including key economic variables
such as household income, total out-of-
pocket prescription costs, and total num-
ber of prescriptions.
It is interesting to note that per-
ceived necessity and harmfulness had
different determinants, as has also been
demonstrated outside of diabetes (5).
Speciﬁcally, perceived necessity was re-
lated to medical factors such as number
of comorbidities, number of medica-
tions, and insulin use. In contrast, per-
ceived medication harmfulness was
related to psychosocial factors, namely
FHL and dissatisfaction with medica-
tion information received. Because only
the latter belief relates to adherence and
outcomes, it seems far more important
to address key psychosocial factors in
nonadherent patients, rather than as-
sume that they fail to grasp the medical
necessity of treatment.
Theﬁndingshighlightmultiplepos-
sible opportunities for clinicians and
health systems. Because cost-related
underusewasexplainedbyfactorsother
than income and costs, approaches in
addition to direct ﬁnancial assistance
might be effective (18). Prescribing cli-
nicians should address patients’ prefer-
ences for information about side effects
and other potential consequences of
pharmacotherapy,especiallyamongpa-
tients with poor FHL. This strategy may
build trust and enhance adherence and
outcomes (19). Because medication un-
deruse related to perceived medication
harmfulness but not perceived neces-
sity, we speculate that patients may
view their prescribed medication as rel-
atively more necessary than safe. If so,
then it would be most productive to ad-
dresspatients’worriesaboutsideeffects
and the personal meanings of taking
medication (20).
Notably, African Americans were
generally more concerned about medica-
tion harmfulness than their Caucasian
counterparts. Moreover, this pattern ex-
ists regardless of income, medication
costs, and FHL. Given that perceived dis-
crimination and distrust in health care
have been documented in African Amer-
icans with diabetes (21), the most cultur-
ally sensitive interventions will be those
that deal directly and skillfully with med-
ication fears.
Screening for nonadherence using
archival data is increasingly feasible, as
health systems transition to integrated
electronic medical record and phar-
macy systems. Nevertheless, educators
and prescribers might consider direct
screening for medication concerns, es-
pecially worry about requiring medica-
tion, likely side effects, dependence
potential, and lifestyle disruption. Such
information may be a useful basis for
patient-centered medication decision
making, ultimately improving health
outcomes.
Study limitations include self-report
assessment methods, which can inﬂate
adherence estimates. However, our de-
tected rates of nonadherence were similar
to those we found in a prior study using
reﬁll data (22), our measurement ap-
proach was prevalidated, and a recent
literature review concluded that stan-
dardized self-report adherence measures
correspond adequately with objective
measures(23).Ourcross-sectionaldesign
precludes the examination of whether the
detected associations persist across time,
making causal inference impossible.
Medication concerns might simply reﬂect
actualadverseeffectsthatpreventthereg-
imen intensiﬁcation required to improve
outcomes. Finally, the single study site
mightnotresembleotherregionsbecause
of geographical variation in community,
cultural, clinical, and economic factors.
Therefore, the results should only be gen-
eralized after careful consideration of the
sample characteristics and any unmea-
sured factors.
We conclude that diabetic patients
with signiﬁcant treatment-related con-
cerns are more likely to underuse their
diabetes and (if applicable) antihyper-
tensive medication. This pattern occurs
whether the underuse is cost-related or
not, consistent with growing evidence
that patients’ adherence in the context
of cost pressures is jointly inﬂuenced by
economic and diverse noneconomic
factors(23).Thisisakeypoint,because
clinicians in economically challenged
communities may feel powerless about
improving patients’ ability to afford
medication. Because medication con-
cerns may directly inﬂuence cost-
related underuse, improved illness
outcome may be achievable by simulta-
neously addressing attitudinal and eco-
nomic issues.
Figure 1— Concern ratings by medication and type of underuse.
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